Citigroup
INFI

Citigroup’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Citigroup’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-107
Closed -$59 – 5984
2022
Q4 		$59 Sell
107
-1,099
-91% -$935 ﹤0.01% 5661
2022
Q3 		$1K Sell
1,206
-3,015
-71% -$3.25K ﹤0.01% 5733
2022
Q2 		$3K Sell
4,221
-931
-18% -$715 ﹤0.01% 5827
2022
Q1 		$6K Sell
5,152
-19,621
-79% -$23.4K ﹤0.01% 5780
2021
Q4 		$56K Buy
24,773
+14,700
+146% +$36.9K ﹤0.01% 5008
2021
Q3 		$34K Buy
10,073
+5,906
+142% +$18.2K ﹤0.01% 4972
2021
Q2 		$12K Sell
4,167
-10,549
-72% -$33.4K ﹤0.01% 5593
2021
Q1 		$48K Buy
+14,716
New +$49.1K ﹤0.01% 4735
2017
Q2 		– Sell
-6,517
Closed -$21K – 7530
2017
Q1 		$21K Sell
6,517
-49,282
-88% -$121K ﹤0.01% 6234
2016
Q4 		$76K Buy
55,799
+37,120
+199% +$48.5K ﹤0.01% 5934
2016
Q3 		$29K Buy
18,679
+12,210
+189% +$18.8K ﹤0.01% 6019
2016
Q2 		$9K Sell
6,469
-29,532
-82% -$138K ﹤0.01% 6609
2016
Q1 		$190K Buy
36,001
+28,128
+357% +$172K ﹤0.01% 5139
2015
Q4 		$61K Sell
7,873
-61,889
-89% -$533K ﹤0.01% 5771
2015
Q3 		$589K Buy
69,762
+59,696
+593% +$551K ﹤0.01% 3591
2015
Q2 		$110K Sell
10,066
-5,725
-36% -$73.5K ﹤0.01% 4922
2015
Q1 		$220K Sell
15,791
-4,879
-24% -$74.6K ﹤0.01% 4445
2014
Q4 		$349K Buy
20,670
+16,764
+429% +$244K ﹤0.01% 4215
2014
Q3 		$52K Sell
3,906
-1,807
-32% -$21.5K ﹤0.01% 5291
2014
Q2 		$73K Sell
5,713
-12,801
-69% -$133K ﹤0.01% 4896
2014
Q1 		$220K Sell
18,514
-2,023
-10% -$27.1K ﹤0.01% 4235
2013
Q4 		$284K Sell
20,537
-18,949
-48% -$268K ﹤0.01% 4334
2013
Q3 		$689K Buy
39,486
+39,347
+28,307% +$753K ﹤0.01% 3193
2013
Q2 		$2K Buy
+139
New +$4.3K ﹤0.01% 6545

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's INFI Position: Q1 2023 in Review

Citigroup sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2023, closing a stake of 107 shares — an estimated $59 sold.

Citigroup first reported a position in INFI in Q2 2013 and held it in 24 quarters. The position peaked at $689K in Q3 2013. 53 funds tracked by Wall St. Rank hold INFI as of Q1 2023.

  • Citigroup reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 107 Infinity Pharmaceuticals, Inc. shares in Q1 2023, an estimated $59.
  • Citigroup first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 24 quarters.
  • Citigroup's Infinity Pharmaceuticals, Inc. position peaked at $689K in Q3 2013.
  • 53 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.